14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
ABOS vs ASTL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ASTL Captures Overall Composite Edge (31.5 SELL vs 49.5 HOLD), While ABOS Leads 4–2 on Growth & Valuation Pillars
ASTL Overall Winner
6-Pillar Tally: ABOS 4 – 2 ASTL
Matrix Metrics: ABOS 4 – 6 ASTL
As of Nov 17, 2026, Algoma Steel Group Inc. Common Shares (ASTL) captures the overall head-to-head institutional edge over Acumen Pharmaceuticals, Inc. (ABOS) on higher Unified Composite conviction (31.5/100 SELL vs. 49.5/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples, R&D & Supply-Chain Moat), while ABOS wins 4–2 across the 6-pillar growth and valuation breakdown. ABOS trades at $0.21 (N/M Forward P/E, 0.0% operating margin) versus ASTL at $5.08 (9.1x Forward P/E, -63.3% operating margin).
Composite vs. Pillar Nuance: While ABOS currently prints a higher short-term Unified Composite Score (49.5/100 HOLD vs. ASTL 31.5/100 SELL), ASTL captures the overall institutional head-to-head verdict (6–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-63.3% vs. 0.0% operating margin) and revenue trajectory (-52.4% vs. +0.0% YoY).
Technical & Structure Timing Caution: ABOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.7); meanwhile ASTL trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABOS vs ASTL. Trailing 12-month operating profitability (ABOS 0.0% vs ASTL -63.3%) and valuation multiples (ABOS N/M vs ASTL 9.1x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Steel value chain with $575.9M market capitalization and -63.3% operating margin.
OpEx & R&D Reinvestment10.1% of Rev ($128M)
90D Engineering Disclosures0 Published
Investor FAQ ABOS vs ASTL Key Questions & Quantitative Answers
As of Nov 17, 2026, Algoma Steel Group Inc. Common Shares (ASTL) captures the overall head-to-head institutional edge over Acumen Pharmaceuticals, Inc. (ABOS) on higher Unified Composite conviction (31.5/100 SELL vs. 49.5/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples, R&D & Supply-Chain Moat), while ABOS wins 4–2 across the 6-pillar growth and valuation breakdown. ABOS trades at $0.21 (N/M Forward P/E, 0.0% operating margin) versus ASTL at $5.08 (9.1x Forward P/E, -63.3% operating margin). Composite vs. Pillar Nuance: While ABOS currently prints a higher short-term Unified Composite Score (49.5/100 HOLD vs. ASTL 31.5/100 SELL), ASTL captures the overall institutional head-to-head verdict (6–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-63.3% vs. 0.0% operating margin) and revenue trajectory (-52.4% vs. +0.0% YoY). Technical & Structure Timing Caution: ABOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.7); meanwhile ASTL trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ABOS leads the Growth & Scale pillar: ABOS posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $329,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with ASTL at -52.4% YoY revenue growth and -93.0% YoY earnings growth on $1.27B TTM revenue (-53.2% gross margin, -63.3% operating margin). On trailing 12-month operating scale, ABOS generates $329,000 in USD-normalized revenue versus $1.27B for ASTL. In operating R&D and SG&A reinvestment, ABOS deploys N/A (0 90-day corporate R&D disclosures) versus 10.1% of Rev ($128M) (0 disclosures) for ASTL.
ASTL screens cheaper on headline valuation multiples. ABOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas ASTL trades at 9.1x Forward P/E, 9.1x Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-12.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABOS (-162.7% ROE) versus ASTL (-139.8% ROE) capital efficiency.
In options market volatility and institutional positioning, ABOS carries 232.4% implied volatility (41st %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.63β · 327% Vol realized risk). By comparison, ASTL carries 70.9% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.65β · 66% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.